Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 188(2): 263-274, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28128853

RESUMO

Citrullination of joint proteins by the protein arginine deiminase (PAD) family of enzymes is recognized increasingly as a key process in the pathogenesis of rheumatoid arthritis. This present study was undertaken to explore the efficacy of a novel PAD4-selective inhibitor, GSK199, in the murine collagen-induced arthritis model of rheumatoid arthritis. Mice were dosed daily from the time of collagen immunization with GSK199. Efficacy was assessed against a wide range of end-points, including clinical disease scores, joint histology and immunohistochemistry, serum and joint citrulline levels and quantification of synovial autoantibodies using a proteomic array containing joint peptides. Administration of GSK199 at 30 mg/kg led to significant effects on arthritis, assessed both by global clinical disease activity and by histological analyses of synovial inflammation, pannus formation and damage to cartilage and bone. In addition, significant decreases in complement C3 deposition in both synovium and cartilage were observed robustly with GSK199 at 10 mg/kg. Neither the total levels of citrulline measurable in joint and serum, nor levels of circulating collagen antibodies, were affected significantly by treatment with GSK199 at any dose level. In contrast, a subset of serum antibodies reactive against citrullinated and non-citrullinated joint peptides were reduced with GSK199 treatment. These data extend our previous demonstration of efficacy with the pan-PAD inhibitor Cl-amidine and demonstrate robustly that PAD4 inhibition alone is sufficient to block murine arthritis clinical and histopathological end-points.


Assuntos
Artrite Experimental/tratamento farmacológico , Artrite Experimental/enzimologia , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/enzimologia , Benzimidazóis/administração & dosagem , Hidrolases/antagonistas & inibidores , Animais , Artrite Experimental/fisiopatologia , Artrite Reumatoide/induzido quimicamente , Artrite Reumatoide/fisiopatologia , Autoanticorpos/sangue , Benzimidazóis/farmacocinética , Osso e Ossos/patologia , Cartilagem/imunologia , Cartilagem/patologia , Citrulina/análise , Citrulina/sangue , Citrulina/imunologia , Colágeno/administração & dosagem , Complemento C3 , Camundongos , Proteína-Arginina Desiminase do Tipo 4 , Proteômica , Membrana Sinovial/imunologia , Membrana Sinovial/fisiopatologia
2.
Clin Oncol (R Coll Radiol) ; 24(1): e18-23, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21752613

RESUMO

AIMS: The association between squamous cell carcinoma of the head and neck (HNSCC) and infection with human papilloma viruses (HPV) has created considerable interest. Rates of primary oropharyngeal cancers have shown increasing incidence and declining age at presentation over the last decade, believed to relate to infection with oncogenic or high-risk subtypes of HPV (HR-HPV). HR-HPV-associated tumours have reportedly improved outcomes when compared with HPV-negative cancers. Within the UK, rates of HR-HPV in HNSCC have not yet been reported. MATERIALS AND METHODS: We analysed consecutive retrospective cases of oropharyngeal cancer presenting between 2004 and 2007. RESULTS: Thirty-seven per cent of 83 oropharyngeal tumours stained positively for p16(INK4A), a marker of HPV infection (73% tonsillar cancers being p16 (INK4A) positive, 30% tongue and 43% floor of mouth tumours). HPV16 DNA was demonstrated in 75% p16 (INK4A) cases. Despite being more advanced with higher T-stage and nodal burden at presentation, HR-HPV-associated HNSCC showed significantly improved rates of disease-free and overall survival, in particular with improved rates of response to radical radiotherapy. CONCLUSION: HPV16 infection seems to be a clinically significant cause of oropharyngeal HNSCC in the UK and the collection of national data should be supported.


Assuntos
Carcinoma de Células Escamosas/virologia , Neoplasias de Cabeça e Pescoço/virologia , Infecções por Papillomavirus/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/radioterapia , DNA Viral/análise , Intervalo Livre de Doença , Feminino , Neoplasias de Cabeça e Pescoço/mortalidade , Neoplasias de Cabeça e Pescoço/radioterapia , Papillomavirus Humano 16 , Humanos , Imuno-Histoquímica , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Infecções por Papillomavirus/epidemiologia , Reação em Cadeia da Polimerase , Reino Unido
3.
Biotechnol Appl Biochem ; 46(Pt 1): 13-26, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16903838

RESUMO

A new method of freeze-thaw is described using experimental data obtained from freezing of purified rhGH (recombinant human growth hormone). The method is based on freezing protein solutions in rectangular rather than cylindrical containers. It is hypothesized that the change in container geometry allows for linear scale-up of the freeze-thaw operation based on equivalency of temperature-time profile. The hypothesis is tested using freeze-thaw data from a miniature (30 ml) and a 2.4 litre container. Computational fluid dynamics techniques are used to simulate the freeze process and the simulations are compared with experimental results. Protein quality is assessed as a function of freeze conditions using dynamic light scattering, circular CD, size-exclusion and reverse-phase HPLC measurements. The results demonstrate the applicability of the new approach. Freezing of rhGH solution at concentrations of approx. 30 mg/ml is shown to be possible with no damage to the molecule for up to five cycles of freeze-thaw. A nitrogen blast chest-freezer is designed and evaluated as part of the process. The refrigeration system and the freeze-thaw method can be used to freeze-thaw bulk protein solutions for development work and has the potential for transfer to manufacturing.


Assuntos
Congelamento , Hormônio do Crescimento/química , Cromatografia em Gel , Cromatografia Líquida de Alta Pressão , Dicroísmo Circular , Equipamentos e Provisões , Proteínas Recombinantes/química
4.
Xenotransplantation ; 9(1): 45-57, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12005104

RESUMO

Research in pig-to-primate xenotransplantation aims to solve the increasing shortage of organs for human allotransplantation and develop new cell- and tissue-based therapies. Progress towards its clinical application has been hampered by the presence of xenoreactive natural antibodies that bind to the foreign cell surface and activate complement, causing humoral graft rejection. Genetic engineering of donor cells and animals to express human complement inhibitors such as hCD59 significantly prolonged graft survival. Strategies to decrease the deposition of natural antibodies were also developed. Expression of human alpha1,2-fucosyltransferase (H transferase, HT) in pigs modifies the cell-surface carbohydrate phenotype resulting in reduced Galalpha1,3-Gal expression and decreased antibody binding. We have developed transgenic pigs that coexpress hCD59 and HT in various cells and tissues to address both natural antibody binding and complement activation. Functional studies with peripheral blood mononuclear cells and aortic endothelial cells isolated from the double transgenic pigs showed that coexpression of hCD59 and HT markedly increased their resistance to human serum-mediated lysis. This resistance was greater than with cells transgenic for either hCD59 or HT alone. Moreover, transgene expression was enhanced and protection maintained in pig endothelial cells that were exposed for 24 h to pro-inflammatory cytokines. These studies suggest that engineering donor pigs to express multiple molecules that address different humoral components of xenograft rejection represents an important step toward enhancing xenograft survival and improving the prospect of clinical xenotransplantation.


Assuntos
Antígenos CD55/genética , Fucosiltransferases/genética , Rejeição de Enxerto/prevenção & controle , Animais , Animais Geneticamente Modificados , Anticorpos Heterófilos/imunologia , Formação de Anticorpos , Antígenos CD/genética , Células Cultivadas , Citotoxicidade Imunológica , Primers do DNA , Endotélio Vascular/citologia , Endotélio Vascular/fisiologia , Rejeição de Enxerto/imunologia , Humanos , Camundongos , Regiões Promotoras Genéticas , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Suínos , Doadores de Tecidos/provisão & distribuição , Galactosídeo 2-alfa-L-Fucosiltransferase
5.
Cytometry ; 30(4): 181-5, 1997 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-9298836

RESUMO

As new diseases and new testing methods emerge, clinical laboratories are faced with updating the skills of their personnel. Complex techniques, such as flow cytometry, require both education and experience to achieve a high level of proficiency. One of the ways to determine areas in which training is needed is to assess laboratory practices and compare them with practices recommended in guidelines or by panels of experts. In this paper we describe practices reported in a written survey of 206 laboratories that perform CD4+ T-cell counts (CD4). We provided a list of alternate practices for each of the key steps in the testing process and asked participants to select the practices they use in their laboratories. Published guidelines and interviews with knowledgeable "key informants" and focus groups of people who perform CD4 testing were used to formulate the questions. We interpreted variations from recommended practices as indicators of training needs. Other factors that can affect performance, such as workload, supervision, and resources, were satisfactory to the respondents. A response rate of 73% (247 of 337 laboratories) revealed that laboratories followed most of the recommended practices. Notable exceptions included some areas of quality control and quality assurance and safety. This paper also describes flow cytometry testing as it was practiced in 1993 shortly after release of some of the testing guidelines and provides a baseline of practices for that time frame.


Assuntos
Contagem de Linfócito CD4/métodos , Laboratórios/normas , Pessoal de Laboratório Médico/educação , Anticorpos Monoclonais , Antígenos CD/análise , Citometria de Fluxo/métodos , Citometria de Fluxo/normas , Guias como Assunto , Humanos , Garantia da Qualidade dos Cuidados de Saúde , Controle de Qualidade , Linfócitos T , Estados Unidos
6.
Hosp Community Psychiatry ; 31(7): 483-90, 1980 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-7380416

RESUMO

The design environment of mental health facilities can facilitate the human interactions essential to treatment and can help in meeting clients' basic needs for safety and security, for self-esteem, and for the development of interpersonal and social skills. To determine the factors in the design of interior spaces that optimize clients' response to therapy, the author made a study of six Indiana community mental health centers. Drawing on that study and other sources, she presents design recommendations for mental health facilities for such areas as reception and admission areas, corridors and stairwells, therapists' offices, inpatient rooms, and dayrooms. Other discussions cover the relation of color, visual patterning, and light, and the selection of materials and finishes.


Assuntos
Centros Comunitários de Saúde Mental , Arquitetura de Instituições de Saúde , Acessibilidade Arquitetônica , Humanos , Decoração de Interiores e Mobiliário , Quartos de Pacientes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA